about
Expression of minichromosome maintenance protein 2 as a marker for proliferation and prognosis in diffuse large B-cell lymphoma: a tissue microarray and clinico-pathological analysis.Resveratrol suppresses constitutive activation of AKT via generation of ROS and induces apoptosis in diffuse large B cell lymphoma cell linesComparative RNA-Seq and microarray analysis of gene expression changes in B-cell lymphomas of Canis familiaris.An epigenetic chromatin remodeling role for NFATc1 in transcriptional regulation of growth and survival genes in diffuse large B-cell lymphomas.Cross-talk between NFkB and the PI3-kinase/AKT pathway can be targeted in primary effusion lymphoma (PEL) cell lines for efficient apoptosis.An uncommon clinical presentation of retroperitoneal non-Hodgkin lymphoma successfully treated with chemotherapy: a case report.Clinical implications of positron emission tomography-negative residual computed tomography masses after chemotherapy for diffuse large B-cell lymphoma.Prognostic evaluation of nodal diffuse large B cell lymphoma by immunohistochemical profiles with emphasis on CD138 expression as a poor prognostic factor.CMC-544 (inotuzumab ozogamicin), an anti-CD22 immuno-conjugate of calicheamicin, alters the levels of target molecules of malignant B-cells.Neurotrophin signaling through tropomyosin receptor kinases contributes to survival and proliferation of non-Hodgkin lymphoma.A rare case of pleural lymphoma.A systems medicine approach for finding target proteins affecting treatment outcomes in patients with non-Hodgkin lymphoma.Serum level of soluble tumor necrosis factor receptor 2 is associated with the outcome of patients with diffuse large B-cell lymphoma treated with the R-CHOP regimen.A third generation regimen VACOP-B with or without adjuvant radiotherapy for aggressive localized non-Hodgkin's lymphoma: report from the Italian Non-Hodgkin's Lymphoma Co-operative Study Group.Serum soluble interleukin-2 receptor (sIL-2R) level is associated with the outcome of patients with diffuse large B cell lymphoma treated with R-CHOP regimens.Expression of PLK1 and survivin in non-Hodgkin's lymphoma treated with CHOP.A salvage chemotherapy of R-P-IMVP16/CBDCA consisting of rituximab, methylprednisolone, ifosfamide, methotrexate, etoposide, and carboplatin for patients with diffuse large B cell lymphoma who had previously received R-CHOP therapy as first-line che
P2860
Q25256909-63B5FA3E-F243-4FB5-A3E9-CB032855492FQ28477048-C593022A-ADB9-4221-96E8-CD59FFF6C130Q30455450-4FC4343E-3210-4507-9E7A-FFC9CEB469E9Q34310916-6CCB5091-DD11-4C32-9FB4-7D7404EAAEEBQ34328449-03A9C558-37D7-417F-9D5E-76E4861F9A6BQ36140335-0EC725F4-B88A-4520-8A88-EF54ACCD6BAEQ37307649-155DF73B-0FE7-4935-8D24-ED3F46BBCFB2Q37313308-103B1848-3FB1-442A-AA06-3E70B75B6DC4Q38355000-B600ED17-8DE6-4EE3-A3F8-B555DE230D0CQ39806462-D7B86A5D-4A66-453B-9F2B-297AB37D269DQ40408529-B9C9A6F1-1661-4E17-8F37-84D6F7C6A871Q41367937-8C4B3BB6-8DC7-43FE-974C-3219ABAFE19AQ44803857-FC8500B5-74ED-45A0-BA5A-DC1B2F258F9CQ44859839-0043846A-5EEF-40F2-916E-04B20616BFDBQ44892511-EE82B308-9EF7-402F-8474-CC40FFF7A9A8Q46734559-DE84A9AE-10CF-45E2-A26E-C695C1D98206Q50247640-99A0DC44-B7D5-4AB1-8D78-BAF54129C73B
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Current trends in large cell lymphoma.
@ast
Current trends in large cell lymphoma.
@en
type
label
Current trends in large cell lymphoma.
@ast
Current trends in large cell lymphoma.
@en
prefLabel
Current trends in large cell lymphoma.
@ast
Current trends in large cell lymphoma.
@en
P2860
P356
P1433
P1476
Current trends in large cell lymphoma.
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.LEU.2403096
P577
2003-10-01T00:00:00Z